International Stem Cell (International Stem Cell) Cash Flow from Financing : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, International Stem Cell paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, International Stem Cell spent $0.00 Mil on financial activities for the three months ended in Mar. 2024.

International Stem Cell Cash Flow from Financing Historical Data

The historical data trend for International Stem Cell's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

International Stem Cell Cash Flow from Financing Chart

International Stem Cell Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

1.30

0.65

0.82

0.25

International Stem Cell Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow from Financing	Get a 7-Day Free Trial															-	-	-	-	-

International Stem Cell Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

International Stem Cell's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

International Stem Cell's Cash from Financing for the quarter that ended in Mar. 2024 is:

	Cash Flow from Financing		(Q: Mar. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

International Stem Cell (OTCPK:ISCO) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

International Stem Cell's issuance of stock for the three months ended in Mar. 2024 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

International Stem Cell's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

International Stem Cell's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. International Stem Cell received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

International Stem Cell's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. International Stem Cell paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

International Stem Cell's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. International Stem Cell received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

International Stem Cell's other financing for the three months ended in Mar. 2024 was $0.00 Mil. International Stem Cell received $0.00 Mil on other financial activities.

International Stem Cell Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of International Stem Cell's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

International Stem Cell (International Stem Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

9745 Businesspark Avenue, San Diego, CA, USA, 92131

Website

https://www.internationalstemcell.com

International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.

Executives

Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin	10 percent owner	1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova	officer: Dir. of Legal Affairs & Oper.	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don	director	2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens	officer: Acting Chief Financial Officer	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi	officer: Chief Financial Officer	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin	director, 10 percent owner	2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak	officer: Interim CFO	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw	officer: Executive Vice President	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund	director	C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc	10 percent owner	5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May	officer: President and COO	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen	officer: Chief Financial Officer	5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus	director, officer: President	2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027